Table 3 Baseline characteristics of the paired longitudinal study

From: The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy

  No-Statin-No-PCSK9 inhibitor therapy (n = 10) Statin monotherapy (n = 15) Add-on PCSK9 inhibitor therapy (n = 16) P value
Mean age (yr) 65.3 ± 8.6 65.3 ± 8.6 66.1 ± 9.1 0.9887
Male sex (%) 50 53 50 0.9846
BMI (kg/m2) 24.8 ± 2.5 23.8 ± 2.6 24.7 ± 3.9 0.9847
Smoking (%) 0 7 0 0.9400
Past history of coronary heart disease (%) 60 67 63 0.9586
Family history of coronary heart disease (%) 30 27 38 0.8705
Heterozygous familial hypercholesterolemia (%) 20 80 81 0.0170
  1. Data were average ± standard deviation. The p-value was determined by using Kruskal–Wallis test